Username or E-mail:

Password:

EULA

Forgot Password

Username:

E-mail:

Password:

EULA

Forgot Password

Already a Member

Username or E-mail

Send Forgot Mail

Back to Login

EULA

İrtibat

Logout

ZNTL

Closed

Zentalis Pharmaceuticals llc

0 (0.00%)

Last Update: 21 Dec 2024 00:05:00

Yesterday: 2.93

Day's Range: 2.89 - 3.1

Send

inforMate

When Written:

17.59

Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company that focuses on developing small-molecule drugs for the treatment of various types of cancer. The company was founded in 2014 and is headquartered in New York City.

Zentalis Pharmaceuticals is committed to discovering and developing innovative therapies that target cancer cells while sparing healthy cells. Their pipeline includes several drug candidates that are currently in clinical trials, including ZN-c5, ZN-c3, and ZN-d5.

ZN-c5 is a novel oral inhibitor of WEE1, a protein kinase that plays a key role in the DNA damage response pathway. ZN-c3 is a selective inhibitor of CDK9, a protein that regulates the transcription of genes involved in cancer cell growth and survival. ZN-d5 is a potent inhibitor of BCL-2, a protein that prevents cancer cells from undergoing apoptosis (programmed cell death).

Zentalis Pharmaceuticals is also developing a companion diagnostic test for ZN-d5, which will help identify patients who are most likely to benefit from treatment with the drug.

Overall, Zentalis Pharmaceuticals is focused on developing targeted therapies that have the potential to improve outcomes for cancer patients.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.

(0)

Send

inforMate

When Written:

17.59

Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company that focuses on the development of small molecule drugs for the treatment of cancer. The company was founded in 2014 and is headquartered in New York City. Zentalis' pipeline includes multiple drug candidates that target various types of cancer, including breast, ovarian, and prostate cancer. The company's lead drug candidate, ZN-c5, is currently being evaluated in a Phase 1/2 clinical trial for the treatment of advanced solid tumors. Zentalis is committed to developing innovative treatments that can improve the lives of cancer patients.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.

(0)

Send

Contact with us

Mail:

Message:

Cancel

Send

IP Adresiniz:3.145.19.231

YASAL UYARI:

   Finansal veriler Unicorn Data Services A.Ş. tarafından sağlanmaktadır. Hisse senedi verileri 15 dakika gecikmeli, Tahvil-Bono-Repo özet verileri de 15 dakika gecikmelidir. Burada sunulan yatırım bilgi, yorum ve tavsiyeler kesinlikle yatırım danışmanlığı hizmeti kapsamında değildir. Yatırım danışmanlığı hizmeti; aracı kurumlar, portföy yönetim şirketleri ve mevduat kabul etmeyen bankalarla müşteri arasında imzalanan yatırım danışmanlığı sözleşmesi çerçevesinde sunulmaktadır. Burada yer alan yorum ve tavsiyeler, ilgili kişilerin kişisel görüşlerine dayanmaktadır. Bu görüşler, mali durumunuz ve risk/getiri tercihlerinizle uygun olmayabilir.

   Bu nedenle, yalnızca burada yer alan bilgilere dayanarak yatırım kararı verirken beklentilerinize uygun sonuçlar elde edemeyebilirsiniz. Web sitemizde veya kullanılan kaynaklarda olabilecek hata ve eksikliklerden, bilgilerin kullanımından doğrudan veya dolaylı olarak kaynaklanabilecek yatırımcıların zararlarından, kar kayıplarından, manevi zararlardan ve üçüncü kişilerin uğrayabileceği zararlardan dolayı Noktacom Medya İnternet Hizmetleri San. ve Tic. A.Ş. hiçbir şekilde sorumlu tutulamaz.

   BİST (Borsa İstanbul) isim ve logosu "Koruma Marka Belgesi" altında korunmakta olup, izinsiz kullanılamaz, kopyalanamaz ve değiştirilemez. BİST adı altında açıklanan tüm bilgilerin telif hakları tamamen BİST'e aittir ve tekrar yayınlanması kesinlikle yasaktır.

PRICE DISCLAIMER:

   The information provided on our website [https://www.fiyaat.com] (the "Site") regarding stock market prices and foreign exchange rates is for general informational purposes only. While we strive to provide accurate and up-to-date information, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained on the Site.

   Any reliance you place on such information is strictly at your own risk. We strongly advise you to conduct your own research and seek professional advice before making any investment or trading decisions based on the information provided on our Site.

   We do not guarantee the accuracy, timeliness, performance, completeness, or suitability of the information and materials found or offered on the Site for any particular purpose. You acknowledge that such information and materials may contain inaccuracies or errors, and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law.

   In no event will we be liable for any loss or damage including, without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of or in connection with the use of the Site.

   Through the Site, you may be able to link to other websites that are not under our control. We have no control over the nature, content, and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorsement of the views expressed within them.

   Every effort is made to keep the Site up and running smoothly. However, we take no responsibility for, and will not be liable for, the Site being temporarily unavailable due to technical issues beyond our control.